La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Stellus Cap Investment a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Stellus Cap Investment..

Stellus Cap Investment (NYSE:SCM) Azioni, Catena delle Opzioni

Stellus Cap Investment

Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through a first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. Business activity of the firm is functioned through the United States and it generates revenue in the form of interest income on debt investments and capital gains and distributions.

Stellus Capital Investment Corporation Common Stock

Stellus Capital Investment Corp

Schwab Strategic Trust Schwab Municipal Bond ETF

Scout Minerals Corp

SILVER CITY MINERALS LTD by SILVER CITY MINERALS LTD

Swisscom AG

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) reported quarterly earnings of $0.40 per share which missed the analyst consensus estimate of $0.46 by 13.04 percent. The company reported quarterly sales of $26.498 million which missed the analyst consensus estimate of $27.355 million by 3.13 percent. This is a 2.46 percent decrease over sales of $27.165 million the same period last year.

Earnings

Earnings Misses

News

Stellus Cap Investment Q3 2024 Adj. EPS $0.40 Misses $0.46 Estimate, Sales $26.498M Miss $27.355M Estimate

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.45 by 11.11 percent. This is a 1.96 percent decrease over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $26.626 million which missed the analyst consensus estimate of $27.006 million by 1.41 percent. This is a 0.15 percent increase over sales of $26.585 million the same period last year.

Earnings Beats

Stellus Cap Investment Q2 2024 Adj. EPS $0.50 Beats $0.45 Estimate, Sales $26.626M Miss $27.006M Estimate

Shares of Indivior PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDV#NASDAQ">INDV</a>) rose sharply in today's pre-market trading after the company posted better-than-expected second-quarter results and announced an accelerated $100 million <a href="https://www.benzinga.com/quote/INDV/earnings">share repurchase program</a>.
Indivior reported quarterly earnings of 44 cents per share which beat the analyst consensus estimate of 14 cents per share. The company reported quarterly sales of $299.00 million which beat the analyst consensus estimate of $296.05 million.
Indivior shares jumped 14.5% to $12.46 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) rose 157.4% to $1.00 in pre-market trading after the company announced the export of nature-derived psilocybin to Australia and said a trial is projected to be initiated shortly following receipt of drug product by trial sites.</li>
<li>BloomZ Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) gained 81.2% to $4.44 in pre-market trading after dipping 43% on Wednesday. BloomZ recently priced its IPO at $4.30 per share.</li>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares climbed 51.4% to $0.4576 in pre-market trading.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) gained 41.5% to $0.2988 in pre-market trading after gaining around 8% on Wednesday.</li>
<li>Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) shares gained 20.8% to $60.90 in pre-market trading after the company reported better-than-expected second-quarter EPS results.</li>
<li>Signing Day Sports, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGN#NYSE">SGN</a>) shares gained 15.9% to $0.2231 in pre-market trading after falling over 12% on Wednesday.</li>
<li>Stellus Capital Investment Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) shares surged 15.6% to $16.41 in pre-market trading.</li>
<li>ELEVAI Labs Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) gained 15.4% to $0.52 in pre-market trading.</li>
<li>Day One Biopharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAWN#NASDAQ">DAWN</a>) shares gained 7.9% to $16.60 in pre-market trading. Ipsen and Day One entered into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>2U, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>) shares fell 67.7% to $1.33 in pre-market trading. 2U announced a strategic agreement with debtholders to eliminate half of debt and infuse $110 million in new capital.</li>
<li>IF Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IROQ#NASDAQ">IROQ</a>) shares declined 59.6% to $6.97 in pre-market trading.</li>
<li>Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) shares fell 22% to $67.85 in pre-market trading after the company reported worse-than-expected second-quarter sales results and issued third-quarter guidance below estimates. Also, the company acquired JenaValve and Endotronix.</li>
<li>Selina Hospitality PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNA#NASDAQ">SLNA</a>) shares fell 19.7% to $0.0367 in pre-market trading after jumping over 75% on Wednesday.</li>
<li>Ostin Technology Group Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) shares declined 18.7% to $0.36 in pre-market trading after gaining around 19% on Wednesday.</li>
<li>MaxLinear, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NYSE">MXL</a>) shares fell 18.1% to $18.25 in pre-market trading after the company reported worse-than-expected second-quarter financial results.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) fell 16.3% to $11.30 in pre-market trading after declining 10% on Wednesday.</li>
<li>Hoth Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) fell 15.9% to $0.8998 in pre-market trading. Hoth Therapeutics shares gained around 11% on Wednesday after the company signed an agreement with LTS Therapy Systems to develop and manufacture the HT-ALZ oral film prototype for Alzheimer&#8217;s disease.</li>
<li>Bone Biologics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares dipped 13% to $1.67 in pre-market trading after jumping 54% on Wednesday.</li>
<li>Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) shares fell 13% to $11.90 in pre-market trading following a second-quarter earnings miss.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39931967/nvidia-mcdonalds-and-2-other-stocks-insiders-are-selling">Nvidia, McDonald&#8217;s And 2 Other Stocks Insiders Are Selling</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

BBLG

BLMZ

CERO

DAWN

ELAB

HOTH

INDV

IROQ

SLNA

TIVC

TWOU

VKTX

Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

B. Riley Securities analyst Bryce Rowe upgrades Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) from Sell to Neutral and raises the price target from $12.5 to $13.25.

Upgrades

Price Target

Analyst Ratings

B. Riley Securities Upgrades Stellus Cap Investment to Neutral, Raises Price Target to $13.25

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) reported quarterly earnings of $0.44 per share which missed the analyst consensus estimate of $0.45 by 2.22 percent. This is a 2.22 percent decrease over earnings of $0.45 per share from the same period last year. The company reported quarterly sales of $25.996 million which missed the analyst consensus estimate of $26.643 million by 2.43 percent. This is a 7.98 percent increase over sales of $24.075 million the same period last year.

Stellus Cap Investment Q1 2024 Adj EPS $0.44 Misses $0.45 Estimate, Sales $25.996M Miss $26.643M Estimate

Oppenheimer analyst Mitchel Penn maintains Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) with a Perform and maintains $14 price target.

Oppenheimer Maintains Perform on Stellus Cap Investment, Maintains $14 Price Target

B. Riley Securities analyst Bryce Rowe reiterates Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) with a Sell and lowers the price target from $13 to $12.5.

Reiteration

B. Riley Securities Reiterates Sell on Stellus Cap Investment, Lowers Price Target to $12.5

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) reported quarterly earnings of $0.500 per share which beat the analyst consensus estimate of $0.450 by 11.11 percent. The company reported quarterly sales of $28.023 million which beat the analyst consensus estimate of $27.408 million by 2.24 percent. This is a 19.93 percent increase over sales of $23.367 million the same period last year.

Stellus Cap Investment Q4 2023 Adj EPS $0.500 Beats $0.450 Estimate, Sales $28.023M Beat $27.408M Estimate

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) is set to give its latest quarterly earnings report on Monday, 2024-03-04. Here's what investors need to know before the announcement.
Analysts estimate that Stellus Cap Investment will report an earnings per share (EPS) of $0.45. 
Stellus Cap Investment bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.02, which was followed by a 4.75% drop in the share price the next day.
Here's a look at Stellus Cap Investment's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.47</td>
<td>0.47</td>
<td>0.44</td>
<td>0.38</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.49</td>
<td>0.51</td>
<td>0.45</td>
<td>0.44</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>-4.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709308823_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Stellus Cap Investment were trading at $12.77 as of February 29. Over the last 52-week period, shares are down 16.93%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/SCM/earnings">To track all earnings releases for Stellus Cap Investment visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Stellus Cap Investment's Earnings: A Preview

B. Riley Securities analyst Bryce Rowe downgrades Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) from Neutral to Sell and announces $13 price target.

Downgrades

B. Riley Securities Downgrades Stellus Cap Investment to Sell, Announces $13 Price Target

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) is set to give its latest quarterly earnings report on Tuesday, 2023-11-07. Here's what investors need to know before the announcement.
Analysts estimate that Stellus Cap Investment will report an earnings per share (EPS) of $0.47. 
Stellus Cap Investment bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.04, which was followed by a 4.17% drop in the share price the next day.
Here's a look at Stellus Cap Investment's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.47</td>
<td>0.44</td>
<td>0.38</td>
<td>0.30</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.51</td>
<td>0.45</td>
<td>0.44</td>
<td>0.35</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.17%</td>
<td>-1.54%</td>
<td>-0.7%</td>
<td>2.4%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2023/1699304510_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Stellus Cap Investment were trading at $13.29 as of November 03. Over the last 52-week period, shares are down 5.61%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/SCM/earnings">To track all earnings releases for Stellus Cap Investment visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Stellus Cap Investment

<h3>Upgrades</h3>
According to Barrington Research, the prior rating for Anika Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) was changed from Market Perform to Outperform. For the second quarter, Anika Therapeutics had an EPS of $0.06, compared to year-ago quarter EPS of $0.12. At the moment, the stock has a 52-week-high of $32.46 and a 52-week-low of $18.21. Anika Therapeutics closed at $18.38 at the end of the last trading period. 
According to B of A Securities, the prior rating for Parsons Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>) was changed from Underperform to Buy. Parsons Corp earned $0.63 in the second quarter, compared to $0.41 in the year-ago quarter. At the moment, the stock has a 52-week-high of $55.28 and a 52-week-low of $38.68. Parsons Corp closed at $54.72 at the end of the last trading period. 
Janney Montgomery Scott upgraded the previous rating for Consolidated Water Co Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWCO#NASDAQ">CWCO</a>) from Neutral to Buy. Consolidated Water Co earned $0.46 in the second quarter, compared to $0.18 in the year-ago quarter. The stock has a 52-week-high of $25.00 and a 52-week-low of $13.39. At the end of the last trading period, Consolidated Water Co closed at $22.63. 
According to Piper Sandler, the prior rating for Coterra Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) was changed from Neutral to Overweight. For the second quarter, Coterra Energy had an EPS of $0.39, compared to year-ago quarter EPS of $1.35. At the moment, the stock has a 52-week-high of $32.46 and a 52-week-low of $22.25. Coterra Energy closed at $28.05 at the end of the last trading period. 
Goldman Sachs upgraded the previous rating for Teledyne Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>) from Neutral to Buy. Teledyne Technologies earned $4.67 in the second quarter, compared to $4.43 in the year-ago quarter. The current stock performance of Teledyne Technologies shows a 52-week-high of $448.71 and a 52-week-low of $325.68. Moreover, at the end of the last trading period, the closing price was at $383.39. 
According to Goldman Sachs, the prior rating for Okta Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) was changed from Sell to Buy. For the first quarter, Okta had an EPS of $0.22, compared to year-ago quarter EPS of $0.27. At the moment, the stock has a 52-week-high of $109.34 and a 52-week-low of $44.13. Okta closed at $71.40 at the end of the last trading period. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>
<h3>Downgrades</h3>
According to DA Davidson, the prior rating for Xos Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOS#NASDAQ">XOS</a>) was changed from Buy to Neutral. Xos earned $0.14 in the second quarter, compared to $0.06 in the year-ago quarter. The current stock performance of Xos shows a 52-week-high of $2.14 and a 52-week-low of $0.21. Moreover, at the end of the last trading period, the closing price was at $0.37. 
According to Jefferies, the prior rating for NeoGames SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGMS#NASDAQ">NGMS</a>) was changed from Buy to Hold. In the second quarter, NeoGames showed an EPS of $0.00, compared to $0.49 from the year-ago quarter. The stock has a 52-week-high of $27.77 and a 52-week-low of $10.85. At the end of the last trading period, NeoGames closed at $27.11. 
According to Argus Research, the prior rating for Boston Properties Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXP#NYSE">BXP</a>) was changed from Buy to Hold. Boston Props earned $1.86 in the second quarter, compared to $1.94 in the year-ago quarter. The current stock performance of Boston Props shows a 52-week-high of $90.54 and a 52-week-low of $46.18. Moreover, at the end of the last trading period, the closing price was at $68.12. 
According to Seibert Williams, the prior rating for Range Resources Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) was changed from Buy to Hold. In the second quarter, Range Resources showed an EPS of $0.30, compared to $1.27 from the year-ago quarter. At the moment, the stock has a 52-week-high of $36.37 and a 52-week-low of $22.61. Range Resources closed at $32.45 at the end of the last trading period. 
According to Wedbush, the prior rating for Atreca Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCEL#NASDAQ">BCEL</a>) was changed from Outperform to Neutral. For the second quarter, Atreca had an EPS of $0.49, compared to year-ago quarter EPS of $0.72. At the moment, the stock has a 52-week-high of $2.78 and a 52-week-low of $0.50. Atreca closed at $0.56 at the end of the last trading period. 
According to Citigroup, the prior rating for Urban Outfitters Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) was changed from Buy to Neutral. For the first quarter, Urban Outfitters had an EPS of $0.56, compared to year-ago quarter EPS of $0.33. The stock has a 52-week-high of $37.81 and a 52-week-low of $18.76. At the end of the last trading period, Urban Outfitters closed at $36.41. 
Oppenheimer downgraded the previous rating for Stellus Capital Investment Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) from Outperform to Perform. In the second quarter, Stellus Cap Investment showed an EPS of $0.51, compared to $0.29 from the year-ago quarter. The current stock performance of Stellus Cap Investment shows a 52-week-high of $16.08 and a 52-week-low of $11.77. Moreover, at the end of the last trading period, the closing price was at $14.83. 
B of A Securities downgraded the previous rating for W.P. Carey Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPC#NYSE">WPC</a>) from Neutral to Underperform. In the second quarter, W.P. Carey showed an EPS of $1.36, compared to $1.31 from the year-ago quarter. At the moment, the stock has a 52-week-high of $89.39 and a 52-week-low of $65.78. W.P. Carey closed at $66.86 at the end of the last trading period. 
According to B of A Securities, the prior rating for EPR Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>) was changed from Buy to Neutral. In the second quarter, EPR Props showed an EPS of $1.28, compared to $1.17 from the year-ago quarter. The current stock performance of EPR Props shows a 52-week-high of $55.90 and a 52-week-low of $33.92. Moreover, at the end of the last trading period, the closing price was at $42.82. 
According to B of A Securities, the prior rating for Keysight Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) was changed from Neutral to Underperform. Keysight Techs earned $2.12 in the second quarter, compared to $1.83 in the year-ago quarter. The current stock performance of Keysight Techs shows a 52-week-high of $189.38 and a 52-week-low of $139.62. Moreover, at the end of the last trading period, the closing price was at $156.54. 
For OpGen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPGN#NASDAQ">OPGN</a>), HC Wainwright &amp; Co. downgraded the previous rating of Buy to Neutral. In the second quarter, OpGen showed an EPS of $0.93, compared to $2.60 from the year-ago quarter. The stock has a 52-week-high of $12.62 and a 52-week-low of $0.24. At the end of the last trading period, OpGen closed at $0.26. 
BMO Capital downgraded the previous rating for Capri Holdings Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>) from Outperform to Market Perform. In the first quarter, Capri Holdings showed an EPS of $0.74, compared to $1.50 from the year-ago quarter. The stock has a 52-week-high of $69.25 and a 52-week-low of $34.17. At the end of the last trading period, Capri Holdings closed at $53.14. 
Piper Sandler downgraded the previous rating for Northern Oil &amp; Gas Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOG#NYSE">NOG</a>) from Overweight to Neutral. For the second quarter, Northern Oil &amp; Gas had an EPS of $1.49, compared to year-ago quarter EPS of $1.72. The current stock performance of Northern Oil &amp; Gas shows a 52-week-high of $42.86 and a 52-week-low of $24.22. Moreover, at the end of the last trading period, the closing price was at $42.02. 
Piper Sandler downgraded the previous rating for Berry Corp (bry) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRY#NASDAQ">BRY</a>) from Overweight to Neutral. For the second quarter, Berry Corp had an EPS of $0.15, compared to year-ago quarter EPS of $0.65. The current stock performance of Berry Corp shows a 52-week-high of $10.74 and a 52-week-low of $6.23. Moreover, at the end of the last trading period, the closing price was at $8.39. 
For Public Service Enterprise Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEG#NYSE">PEG</a>), UBS downgraded the previous rating of Buy to Neutral. Public Service Enterprise earned $0.70 in the second quarter, compared to $0.64 in the year-ago quarter. The stock has a 52-week-high of $69.90 and a 52-week-low of $52.53. At the end of the last trading period, Public Service Enterprise closed at $60.87. 
For Braemar Hotels &amp; Resorts Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHR#NYSE">BHR</a>), B. Riley Securities downgraded the previous rating of Buy to Neutral. In the second quarter, Braemar Hotels &amp; Resorts showed an EPS of $0.20, compared to $0.37 from the year-ago quarter. The current stock performance of Braemar Hotels &amp; Resorts shows a 52-week-high of $5.85 and a 52-week-low of $2.77. Moreover, at the end of the last trading period, the closing price was at $2.91. 
Bernstein downgraded the previous rating for Marriott International Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) from Outperform to Market Perform. In the second quarter, Marriott Intl showed an EPS of $2.26, compared to $1.80 from the year-ago quarter. At the moment, the stock has a 52-week-high of $210.98 and a 52-week-low of $135.90. Marriott Intl closed at $208.51 at the end of the last trading period. 
According to Barclays, the prior rating for CF Industries Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) was changed from Overweight to Equal-Weight. For the second quarter, CF Industries Holdings had an EPS of $2.70, compared to year-ago quarter EPS of $6.19. The stock has a 52-week-high of $119.54 and a 52-week-low of $60.08. At the end of the last trading period, CF Industries Holdings closed at $79.49. 
Barclays downgraded the previous rating for The Mosaic Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>) from Equal-Weight to Underweight. Mosaic earned $1.04 in the second quarter, compared to $3.64 in the year-ago quarter. The stock has a 52-week-high of $63.16 and a 52-week-low of $31.44. At the end of the last trading period, Mosaic closed at $41.69. 
According to Barclays, the prior rating for Nutrien Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) was changed from Overweight to Underweight. In the second quarter, Nutrien showed an EPS of $2.53, compared to $5.85 from the year-ago quarter. The current stock performance of Nutrien shows a 52-week-high of $102.70 and a 52-week-low of $52.23. Moreover, at the end of the last trading period, the closing price was at $66.49. 
Jefferies downgraded the previous rating for Chindata Group Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CD#NASDAQ">CD</a>) from Buy to Hold. Chindata Group Holdings earned $0.12 in the first quarter, compared to $0.07 in the year-ago quarter. The current stock performance of Chindata Group Holdings shows a 52-week-high of $9.21 and a 52-week-low of $4.86. Moreover, at the end of the last trading period, the closing price was at $8.11. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>
<h3>Initiations</h3>
Northland Capital Markets initiated coverage on Manitex International Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTX#NASDAQ">MNTX</a>) with an Outperform rating. The price target for Manitex International is set to $10.00. For the second quarter, Manitex International had an EPS of $0.08, compared to year-ago quarter EPS of $0.05. The stock has a 52-week-high of $6.26 and a 52-week-low of $3.48. At the end of the last trading period, Manitex International closed at $5.05. 
For PLAYSTUDIOS Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYPS#NASDAQ">MYPS</a>), BTIG initiated coverage, by setting the current rating at Neutral. For the second quarter, PLAYSTUDIOS had an EPS of $0.01, compared to year-ago quarter EPS of $0.04. At the moment, the stock has a 52-week-high of $5.00 and a 52-week-low of $3.25. PLAYSTUDIOS closed at $3.82 at the end of the last trading period. 
Truist Securities initiated coverage on ODDITY Tech Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) with a Hold rating. The price target for ODDITY Tech is set to $54.00. For the second quarter, ODDITY Tech had an EPS of $0.56, compared to year-ago quarter EPS of $0.33. At the moment, the stock has a 52-week-high of $56.00 and a 52-week-low of $46.28. ODDITY Tech closed at $52.38 at the end of the last trading period. 
TD Cowen initiated coverage on Sana Biotechnology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) with a Market Perform rating. In the second quarter, Sana Biotechnology showed an EPS of $0.45, compared to $0.47 from the year-ago quarter. The stock has a 52-week-high of $8.75 and a 52-week-low of $2.99. At the end of the last trading period, Sana Biotechnology closed at $5.46. 
With a Neutral rating, B of A Securities initiated coverage on ODDITY Tech Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>). The price target seems to have been set at $60.00 for ODDITY Tech. In the second quarter, ODDITY Tech showed an EPS of $0.56, compared to $0.33 from the year-ago quarter. At the moment, the stock has a 52-week-high of $56.00 and a 52-week-low of $46.28. ODDITY Tech closed at $52.38 at the end of the last trading period. 
Morgan Stanley initiated coverage on ODDITY Tech Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) with a Equal-Weight rating. The price target for ODDITY Tech is set to $57.00. ODDITY Tech earned $0.56 in the second quarter, compared to $0.33 in the year-ago quarter. The current stock performance of ODDITY Tech shows a 52-week-high of $56.00 and a 52-week-low of $46.28. Moreover, at the end of the last trading period, the closing price was at $52.38. 
With a Buy rating, UBS initiated coverage on CymaBay Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBAY#NASDAQ">CBAY</a>). The price target seems to have been set at $18.00 for CymaBay Therapeutics. For the second quarter, CymaBay Therapeutics had an EPS of $0.01, compared to year-ago quarter EPS of $0.31. At the moment, the stock has a 52-week-high of $14.19 and a 52-week-low of $3.15. CymaBay Therapeutics closed at $13.47 at the end of the last trading period. 
With a Buy rating, HSBC initiated coverage on Monster Beverage Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>). The price target seems to have been set at $72.00 for Monster Beverage. Monster Beverage earned $0.39 in the second quarter, compared to $0.26 in the year-ago quarter. The current stock performance of Monster Beverage shows a 52-week-high of $60.47 and a 52-week-low of $42.80. Moreover, at the end of the last trading period, the closing price was at $58.18. 
Needham initiated coverage on Agilysys Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) with a Buy rating. The price target for Agilysys is set to $92.00. Agilysys earned $0.18 in the first quarter, compared to $0.21 in the year-ago quarter. The current stock performance of Agilysys shows a 52-week-high of $88.16 and a 52-week-low of $46.01. Moreover, at the end of the last trading period, the closing price was at $70.08. 
Telsey Advisory Group initiated coverage on Academy Sports and Outdoors Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) with an Outperform rating. The price target for Academy Sports is set to $72.00. For the first quarter, Academy Sports had an EPS of $1.30, compared to year-ago quarter EPS of $1.72. The stock has a 52-week-high of $69.02 and a 52-week-low of $40.70. At the end of the last trading period, Academy Sports closed at $55.19. 
Goldman Sachs initiated coverage on Ducommun Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DCO#NYSE">DCO</a>) with a Neutral rating. The price target for Ducommun is set to $52.00. In the second quarter, Ducommun showed an EPS of $0.54, compared to $0.76 from the year-ago quarter. At the moment, the stock has a 52-week-high of $58.28 and a 52-week-low of $39.46. Ducommun closed at $45.76 at the end of the last trading period. 
JMP Securities initiated coverage on ODDITY Tech Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) with a Market Outperform rating. The price target for ODDITY Tech is set to $66.00. In the second quarter, ODDITY Tech showed an EPS of $0.56, compared to $0.33 from the year-ago quarter. The current stock performance of ODDITY Tech shows a 52-week-high of $56.00 and a 52-week-low of $46.28. Moreover, at the end of the last trading period, the closing price was at $52.38. 
With a Neutral rating, Goldman Sachs initiated coverage on ODDITY Tech Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>). The price target seems to have been set at $59.00 for ODDITY Tech. For the second quarter, ODDITY Tech had an EPS of $0.56, compared to year-ago quarter EPS of $0.33. The current stock performance of ODDITY Tech shows a 52-week-high of $56.00 and a 52-week-low of $46.28. Moreover, at the end of the last trading period, the closing price was at $52.38. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

Initiation

Intraday Update

AGYS

ANIK

BCEL

CBAY

CPRI

CTRA

CWCO

KEYS

MNST

MNTX

MYPS

NGMS

OKTA

OPGN

SANA

URBN

Benzinga's Top Ratings Upgrades, Downgrades For August 14, 2023

B. Riley Securities analyst Bryce Rowe maintains Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) with a Neutral and raises the price target from $14 to $14.25.

B. Riley Securities Maintains Neutral on Stellus Cap Investment, Raises Price Target to $14.25

Oppenheimer analyst Mitchel Penn downgrades Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) from Outperform to Perform and announces $15 price target.

Oppenheimer Downgrades Stellus Cap Investment to Perform, Announces $15 Price Target

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.47 by 8.51 percent. This is a 75.86 percent increase over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $26.59 million which beat the analyst consensus estimate of $25.50 million by 4.25 percent. This is a 65.03 percent increase over sales of $16.11 million the same period last year.

Stellus Cap Investment Q2 Adj EPS $0.51 Beats $0.47 Estimate, Sales $26.59M Beat $25.50M Estimate

<h3>Upgrades</h3>
According to B of A Securities, the prior rating for West Pharmaceutical Services Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) was changed from Neutral to Buy. West Pharmaceutical Servs earned $1.98 in the first quarter, compared to $2.30 in the year-ago quarter. The current stock performance of West Pharmaceutical Servs shows a 52-week-high of $376.72 and a 52-week-low of $207.15. Moreover, at the end of the last trading period, the closing price was at $359.80. 
For Abcam PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABCM#NASDAQ">ABCM</a>), B of A Securities upgraded the previous rating of Neutral to Buy. NoneThe stock has a 52-week-high of $19.25 and a 52-week-low of $12.48. At the end of the last trading period, Abcam closed at $19.06. 
UBS upgraded the previous rating for AutoZone Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) from Neutral to Buy. In the third quarter, AutoZone showed an EPS of $34.12, compared to $29.03 from the year-ago quarter. The current stock performance of AutoZone shows a 52-week-high of $2750.00 and a 52-week-low of $1964.93. Moreover, at the end of the last trading period, the closing price was at $2497.37. 
JP Morgan upgraded the previous rating for MorphoSys AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOR#NASDAQ">MOR</a>) from Underweight to Overweight. MorphoSys earned $0.35 in the first quarter, compared to $4.03 in the year-ago quarter. At the moment, the stock has a 52-week-high of $7.66 and a 52-week-low of $3.19. MorphoSys closed at $7.07 at the end of the last trading period. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>
<h3>Downgrades</h3>
New Street Research downgraded the previous rating for Applied Materials Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) from Buy to Neutral. For the second quarter, Applied Mat had an EPS of $2.00, compared to year-ago quarter EPS of $1.85. At the moment, the stock has a 52-week-high of $142.53 and a 52-week-low of $71.18. Applied Mat closed at $140.11 at the end of the last trading period. 
For Truist Financial Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>), Odeon Capital downgraded the previous rating of Buy to Hold. In the first quarter, Truist Finl showed an EPS of $1.09, compared to $1.23 from the year-ago quarter. At the moment, the stock has a 52-week-high of $53.34 and a 52-week-low of $25.56. Truist Finl closed at $32.22 at the end of the last trading period. 
According to TD Cowen, the prior rating for Bausch Health Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) was changed from Outperform to Market Perform. In the first quarter, Bausch Health Companies showed an EPS of $0.52, compared to $0.72 from the year-ago quarter. The current stock performance of Bausch Health Companies shows a 52-week-high of $10.23 and a 52-week-low of $4.00. Moreover, at the end of the last trading period, the closing price was at $7.44. 
For RPC Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RES#NYSE">RES</a>), Citigroup downgraded the previous rating of Neutral to Sell. In the first quarter, RPC showed an EPS of $0.39, compared to $0.07 from the year-ago quarter. NoneAt the moment, the stock has a 52-week-high of $11.40 and a 52-week-low of $5.71. RPC closed at $7.81 at the end of the last trading period. 
For NexTier Oilfield Solutions Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEX#NYSE">NEX</a>), Citigroup downgraded the previous rating of Buy to Neutral. In the first quarter, NexTier Oilfield showed an EPS of $0.66, compared to $0.08 from the year-ago quarter. The stock has a 52-week-high of $11.36 and a 52-week-low of $6.67. At the end of the last trading period, NexTier Oilfield closed at $9.52. 
According to B of A Securities, the prior rating for Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) was changed from Buy to Neutral. In the fourth quarter, Evotec showed an EPS of $0.08, compared to $0.23 from the year-ago quarter. At the moment, the stock has a 52-week-high of $15.04 and a 52-week-low of $7.80. Evotec closed at $11.85 at the end of the last trading period. 
B of A Securities downgraded the previous rating for SoFi Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) from Buy to Neutral. In the first quarter, SoFi Techs showed an EPS of $0.05, compared to $0.14 from the year-ago quarter. At the moment, the stock has a 52-week-high of $10.23 and a 52-week-low of $4.25. SoFi Techs closed at $9.55 at the end of the last trading period. 
Piper Sandler downgraded the previous rating for SoFi Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) from Overweight to Neutral. For the first quarter, SoFi Techs had an EPS of $0.05, compared to year-ago quarter EPS of $0.14. The stock has a 52-week-high of $10.23 and a 52-week-low of $4.25. At the end of the last trading period, SoFi Techs closed at $9.55. 
According to JP Morgan, the prior rating for Mersana Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>) was changed from Overweight to Neutral. For the first quarter, Mersana Therapeutics had an EPS of $0.52, compared to year-ago quarter EPS of $0.59. The stock has a 52-week-high of $9.62 and a 52-week-low of $2.94. At the end of the last trading period, Mersana Therapeutics closed at $3.89. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>
<h3>Initiations</h3>
With a Neutral rating, DA Davidson initiated coverage on Elastic NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>). The price target seems to have been set at $60.00 for Elastic. In the fourth quarter, Elastic showed an EPS of $0.22, compared to $0.16 from the year-ago quarter. The current stock performance of Elastic shows a 52-week-high of $91.19 and a 52-week-low of $46.18. Moreover, at the end of the last trading period, the closing price was at $69.46. 
With a Buy rating, Maxim Group initiated coverage on Bionomics Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>). The price target seems to have been set at $7.00 for Bionomics. 
With a Neutral rating, Ladenburg Thalmann initiated coverage on Alliant Energy Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNT#NASDAQ">LNT</a>). The price target seems to have been set at $52.50 for Alliant Energy. In the first quarter, Alliant Energy showed an EPS of $0.65, compared to $0.77 from the year-ago quarter. NoneThe stock has a 52-week-high of $64.59 and a 52-week-low of $47.23. At the end of the last trading period, Alliant Energy closed at $53.75. 
With a Hold rating, Truist Securities initiated coverage on Hagerty Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGTY#NYSE">HGTY</a>). The price target seems to have been set at $11.00 for Hagerty. In the first quarter, Hagerty showed an EPS of $0.04, compared to $0.01 from the year-ago quarter. The current stock performance of Hagerty shows a 52-week-high of $13.58 and a 52-week-low of $7.82. Moreover, at the end of the last trading period, the closing price was at $9.17. 
Wells Fargo initiated coverage on MorphoSys AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOR#NASDAQ">MOR</a>) with an Overweight rating. The price target for MorphoSys is set to $17.00. In the first quarter, MorphoSys showed an EPS of $0.35, compared to $4.03 from the year-ago quarter. The current stock performance of MorphoSys shows a 52-week-high of $7.66 and a 52-week-low of $3.19. Moreover, at the end of the last trading period, the closing price was at $7.07. 
Wells Fargo initiated coverage on Bio-Rad Laboratories Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) with an Overweight rating. The price target for Bio-Rad Laboratories is set to $550.00. In the first quarter, Bio-Rad Laboratories showed an EPS of $3.34, compared to $4.94 from the year-ago quarter. The current stock performance of Bio-Rad Laboratories shows a 52-week-high of $570.22 and a 52-week-low of $345.53. Moreover, at the end of the last trading period, the closing price was at $379.06. 
Wells Fargo initiated coverage on Neogen Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) with an Overweight rating. The price target for Neogen is set to $22.00. For the third quarter, Neogen had an EPS of $0.12, compared to year-ago quarter EPS of $0.15. At the moment, the stock has a 52-week-high of $25.00 and a 52-week-low of $10.49. Neogen closed at $19.81 at the end of the last trading period. 
With a Buy rating, B. Riley Securities initiated coverage on Ares Capital Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCC#NASDAQ">ARCC</a>). The price target seems to have been set at $20.50 for Ares Capital. Ares Capital earned $0.57 in the first quarter, compared to $0.42 in the year-ago quarter. At the moment, the stock has a 52-week-high of $20.75 and a 52-week-low of $16.54. Ares Capital closed at $18.65 at the end of the last trading period. 
Roth MKM initiated coverage on GigaCloud Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) with a Buy rating. The price target for GigaCloud Tech is set to $13.00. For the first quarter, GigaCloud Tech had an EPS of $0.39, compared to year-ago quarter EPS of $0.13. The current stock performance of GigaCloud Tech shows a 52-week-high of $61.98 and a 52-week-low of $4.14. Moreover, at the end of the last trading period, the closing price was at $7.84. 
With a Buy rating, Jefferies initiated coverage on LendingClub Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>). The price target seems to have been set at $13.50 for LendingClub. LendingClub earned $0.13 in the first quarter, compared to $0.39 in the year-ago quarter. The stock has a 52-week-high of $15.78 and a 52-week-low of $6.30. At the end of the last trading period, LendingClub closed at $9.64. 
With a Neutral rating, UBS initiated coverage on Guess? Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>). The price target seems to have been set at $22.00 for Guess. In the first quarter, Guess showed an EPS of $0.07, compared to $0.24 from the year-ago quarter. The current stock performance of Guess shows a 52-week-high of $24.14 and a 52-week-low of $14.27. Moreover, at the end of the last trading period, the closing price was at $20.85. 
UBS initiated coverage on Oxford Industries Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) with a Neutral rating. The price target for Oxford Industries is set to $110.00. In the first quarter, Oxford Industries showed an EPS of $3.78, compared to $3.50 from the year-ago quarter. At the moment, the stock has a 52-week-high of $123.37 and a 52-week-low of $82.16. Oxford Industries closed at $102.57 at the end of the last trading period. 
With a Buy rating, Jefferies initiated coverage on Atlanticus Holdings Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATLC#NASDAQ">ATLC</a>). The price target seems to have been set at $50.00 for Atlanticus Holdings. In the first quarter, Atlanticus Holdings showed an EPS of $1.08, compared to $1.96 from the year-ago quarter. At the moment, the stock has a 52-week-high of $42.97 and a 52-week-low of $21.65. Atlanticus Holdings closed at $42.97 at the end of the last trading period. 
With a Neutral rating, B. Riley Securities initiated coverage on Stellus Capital Investment Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>). The price target seems to have been set at $14.00 for Stellus Cap Investment. In the first quarter, Stellus Cap Investment showed an EPS of $0.45, compared to $0.29 from the year-ago quarter. At the moment, the stock has a 52-week-high of $16.08 and a 52-week-low of $11.06. Stellus Cap Investment closed at $14.02 at the end of the last trading period. 
B. Riley Securities initiated coverage on Sixth Street Specialty Lending Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSLX#NYSE">TSLX</a>) with a Buy rating. The price target for Sixth Street Specialty is set to $21.00. For the first quarter, Sixth Street Specialty had an EPS of $0.55, compared to year-ago quarter EPS of $0.49. The stock has a 52-week-high of $19.83 and a 52-week-low of $16.03. At the end of the last trading period, Sixth Street Specialty closed at $18.55. 
BTIG initiated coverage on Olo Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLO#NYSE">OLO</a>) with a Neutral rating. Olo earned $0.03 in the first quarter, compared to $0.01 in the year-ago quarter. At the moment, the stock has a 52-week-high of $14.07 and a 52-week-low of $5.74. Olo closed at $7.37 at the end of the last trading period. 
With a Buy rating, BTIG initiated coverage on Shift4 Payments Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>). The price target seems to have been set at $83.00 for Shift4 Payments. In the first quarter, Shift4 Payments showed an EPS of $0.51, compared to $0.15 from the year-ago quarter. The stock has a 52-week-high of $76.40 and a 52-week-low of $29.41. At the end of the last trading period, Shift4 Payments closed at $63.79. 
BTIG initiated coverage on Toast Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) with a Neutral rating. For the first quarter, Toast had an EPS of $0.16, compared to year-ago quarter EPS of $0.20. The current stock performance of Toast shows a 52-week-high of $26.04 and a 52-week-low of $12.16. Moreover, at the end of the last trading period, the closing price was at $23.03. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

ABCM

AMAT

ARCC

ATLC

BNOX

ESTC

FOUR

HGTY

Morgan Stanley Capital Protected Notes for S&P 500 Index

MRSN

NEOG

SOFI

TOST

TSLX

Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2023

B. Riley Securities analyst Bryce Rowe initiates coverage on Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) with a Neutral rating and announces Price Target of $14.

B. Riley Securities Initiates Coverage On Stellus Cap Investment with Neutral Rating, Announces Price Target of $14

Keefe, Bruyette &amp; Woods analyst Ryan Lynch maintains Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) with a Market Perform and lowers the price target from $15.5 to $15.

Keefe, Bruyette & Woods Maintains Market Perform on Stellus Cap Investment, Lowers Price Target to $15

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) reported its Q1 earnings results on Tuesday, May 9, 2023 at 06:15 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Stellus Cap Investment beat estimated earnings by 2.27%, reporting an EPS of $0.45 versus an estimate of $0.44.
Revenue was up $8.58 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.06 which was followed by a 0.7% drop in the share price the next day.
Here's a look at Stellus Cap Investment's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
<th>Q2 2022</th>
<th>Q1 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.38</td>
<td>0.30</td>
<td>0.29</td>
<td>0.30</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.44</td>
<td>0.35</td>
<td>0.29</td>
<td>0.29</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>21.45M</td>
<td>17.59M</td>
<td>16.45M</td>
<td>16.33M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>23.37M</td>
<td>20.14M</td>
<td>16.11M</td>
<td>15.49M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Stellus Cap Investment <a href="https://www.benzinga.com/quote/SCM/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Stellus Cap Investment: Q1 Earnings Insights

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.44 by 2.27 percent. This is a 55.17 percent increase over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $24.07 million which beat the analyst consensus estimate of $23.61 million by 1.97 percent. This is a 55.38 percent increase over sales of $15.49 million the same period last year.

Stellus Cap Investment Q1 EPS $0.45 Beats $0.44 Estimate, Sales $24.07M Beat $23.61M Estimate

Stellus Capital: Consistent Performance But Still Awaiting A Better Entry

84 Monthly Paid Dividend Stocks And 80 Funds For September

Stellus Capital: Optically Attractive, But With Speculative Leverage Level

Stellus Capital Investment declares $0.1333 dividend

72 Monthly Paid Dividend Stocks And 80 Funds For October

Here are the major earnings after the close today

Stellus Capital Investment NII of $0.40 misses by $0.04

Robert T. Ladd, Chief Executive Officer of Stellus, stated, "I am pleased to report solid operating results for the quarter ended September 30, 202...

Stellus Capital reports Q3 core NII $10.62 vs 39c last year

Stellus Capital Investment Corporation (SCM) Q3 2024 Earnings Call Transcript

Stellus Capital Investment ( ($SCM) ) has released its Q3 earnings. Here is a breakdown of the information Stellus Capital Investment presented to ...

Comments

Stellus Cap Investment

Stellus Cap Investment (SCM) Opzioni

Stellus Cap Investment (NYSE:SCM) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO